Target	% Remaining NVR	Reference	Target	% Remaining NVR	Reference
nNOS	32.3	Bonvento, G., N. et al., 2000	**ACh**	41.0	Arneric, S.P., et al., 1987
(Mean 35.8%)	21.8	Burke, M. and C. Buhrle., 2006	(Mean 46.4%)	60.0	Biesold, D., et al., 1989
	79.0	Cholet, N., et al., 1997		15.0	Kocharyan, A., et al., 2008
	45.0	Iadecola, C., G., et al., 1993		60.0	Kocharyan, A., et al., 2008
	50.0	Kitaura, H., et al., 2007		56.0	Zhang, F., et al., 1995
	38.9	Lindauer, U., et al., 1999	**Adenosine**	59.2	Dirnagl, U., et al., 1994
	40.0	Offenhauser, N., K., et al., 2005	(Mean 46.6%)	66.8	Ko, K. R., et al., 1990
	-1.1	Stefanovic, B., et al., 2007		47.3	Ko, K. R., et al., 1990
	51.0	Yang, G. and Iadecola, C., 1997		29.7	Meno, J.R., et al., 2005
	10.0	Yang, G., et al., 1999		30.0	Meno, J.R., et al., 2005
	27.0	Yang, G., et al., 2003	**COX-2**	50.0	Bakalova, R., T. et al., 2002
Multiple	41.9	Dirnagl, U., et al., 1994	(Mean 53.3%)	47.3	Lecrux, C., et al., 2011
(Mean 39.0%)	30.0	Golanov, E.V., Reis, D.J., 1994		53.0	Niwa, K., et al., 2000
	33.3	Leithner, C., et al., 2010		63.0	Niwa, K., et al., 2000
	31.8	Peng, X., C., et al., 2004	**AMPA/NMDA**	66.7	Calcinaghi, N., et al., 2011
	64.0	Petzold, G.C., et al., 2008	(Mean 55.8%)	62.2	Lecrux, C., et al., 2011
	33.3	Tarantini, S., et al., 2015		65.5	Petzold, G. C., et al., 2008
NOS	40.0	Adachi, T., et al., 1992		29.0	Yang, G., et al., 1999
(Mean 41.8%)	40.0	Akgoren, N., et al., 1997	**COX**	45.0	Bakalova, R. T., et al. 2002
	62.6	Dirnagl, U., et al., 1993	(Mean 56.3%)	47.2	Bruhn, H., et al., 2001
	39.0	Golanov, E.V., Reis, D.J., 1994		62.0	Golanov, E.V., Reis, D.J., 1994
	20.0	Iadecola, C., G., et al., 1993		50.0	St Lawrence, K.S., et al. 2003
	0.0	Ido, Y., et al., 2004		77.4	St Lawrence, K.S., et al. 2003
	53.3	Irikura, K., et al., 1994	**K+ Channels**	108.3	Hosford, P.S., et al., 2018
	50.0	Kitaura, H., et al., 2007	(Mean 59.8%)	60.0	Longden, T.A., et al., 2011
	52.3	Ngai, A.C., et al., 1995		19.9	Longden, T.A., et al., 2017
	36.4	Peng, X., C., et al., 2004		51.0	Longden, T.A., et al., 2017
	29.1	Raszkiewicz, et al., 1992	**mGluR**	122.9	Calcinaghi, N., et al., 2011
	52.9	Toth, P., et al., 2015	(Mean 63.0%)	59.5	Lecrux, C., et al., 2011
	53.0	Yang, G. and C. Iadecola., 1997		46.0	Petzold, G. C., et al., 2008
	57.0	Zhang, F., et al., 1995		51.7	Sloan, H.L., et al., 2010
ATP	32.4	Mishra, A., et al., 2016		34.8	Zonta, M., et al., 2003
(Mean 43.0%)	48.4	Toth, P., et al., 2015	**GABA**	54.0	Kocharyan, A., P., et al., 2008
	48.1	Wells, J.A., et al., 2015	(Mean 75.6%)	72.0	Kocharyan, A., P., et al., 2008
Epoxygenase	60.0	Lecrux, C., et al., 2011		90.0	Kocharyan, A., P., et al., 2008
(Mean 45.5%)	30.6	Peng, X, et al., 2002		69.6	Lecrux, C., et al., 2011
	32.3	Peng, X, et al., 2002		92.6	Lecrux, C., et al., 2011
	68.2	Peng, X., C., et al., 2004	**COX-1**	103.4	Niwa, K., et al., 2001
	36.4	Peng, X., C., et al., 2004	(Mean 85.5%)	88.9	Niwa, K., et al., 2001
				64.0	Petzold, G. C., et al., 2008

Supplementary Table 1| Individual data points showing the effect of target pharmacological blockade/genetic deletion in vivo expressed in percent of neurovascular response (NVR) remaining (as plotted in Figure 2) with corresponding references to the original sources.